Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid sales. Merck's stock has surged 31% year-to-date, reflecting confidence in its pipeline despite the upcoming KEYTRUDA patent cliff. Investors see Lilly as the leader in incretin drugs, Merck as fairly valued with growth potential, and Novo as facing near-term challenges.
Eli Lilly became the first pharmaceutical company valued over $1 trillion, driven by strong revenue growth and promising drugs like retatrutide and orforglipron. The company reported a 47.67% revenue increase in Q2 and raised its 2026 revenue guidanc...
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
J.P. Morgan Life Sciences Private Capital has named Bruce N. Rogers, Ph.D., as a Venture Partner. Dr. Rogers brings extensive experience in drug discovery and development, having led significant roles at Morphic Therapeutic and Pfizer. His expertise ...
Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's an...
